I le aso 24 o Novema, 2021, na faʻasalalau ai e Kintor Pharma o le National Medical Products Administration (NMPA) a Saina na faʻamalamalamaina le maliega mo le suʻesuʻega vaega III o le KX-826.

I le aso 20 o Tesema, 2021, na fa'ataunu'u manuia ai le fonotaga amata i le au su'esu'e autu mo le KX-826 vaega III fa'ata'ita'iga. O le Falemai o Tagata o le Iunivesite o Peking ma le Falemai o Huashan o loʻo fesoʻotaʻi ma le Iunivesite o Fudan na taʻitaʻia le faamasinoga, ma 26 falemaʻi e auai. Ina ua maeʻa le taʻitaʻia o le vaega II o le faʻataʻitaʻiga a le KX-826 i Saina mo togafitiga o le AGA, na toe galulue faʻatasi ai le Polofesa Zhang Jianzhong mai le Falemaʻi Tagata a le Iunivesite o Peking ma le Polofesa Yang Qinping mai le Falemai o Huashan e fesoʻotaʻi ma le Iunivesite o Fudan e avea ma taʻitaʻi suʻesuʻe autu ( ta'ita'i PIs) ole vaega taua ole Vaega III Fa'amasinoga Fa'afoma'i ole KX-826. I le fonotaga a tagata suʻesuʻe, toeitiiti atoa le 100 tagata atamamai mai le 26 falemaʻi i Saina na faʻalogologo i le lipoti i le aoga ma le saogalemu o le KX-826's Phase II faʻataʻitaʻiga faʻataʻitaʻi. O Polofesa Zhang Jianzhong na fa'ai'uina le fonotaga ma fa'amalosia PI uma ina ia auai i lenei su'esu'ega taua ma le maualuga ma le lelei.

O Dr. Youzhi Tong, na faavaeina, Taitaifono, ma le Ofisa Sili o Pulega o Kintor Pharma, fai mai, "O le 'au a Kintor na faʻatinoina ma le maualuga maualuga mai le kilia a le NMPA i le faʻaogaina muamua o lenei vaega III faʻataʻitaʻiga faʻataʻitaʻi ma le tusa ma le tasi le masina. Ole vaega III ole su'esu'ega ile falema'i ole a faia ile 26 pito i luga ole dermatology fa'alapotopotoga fa'afoma'i i Saina. Matou te tulimatai atu i le faʻamaeʻaina o mataupu e 416 ua fuafuaina ia Iuni 2022, ma le suʻesuʻega faafomaʻi tulitatao (6 masina suʻesuʻega + 1 masina tulitatao) i totonu o le tausaga. Faatasi ai ma le sini o le faʻamaeʻaina o le vaega III faʻataʻitaʻiga faʻataʻitaʻiga i lenei tausaga, o loʻo matou faʻavavevaveina le faagasologa ma faʻamoemoe o le KX-826 o le a manuia ai tagata gasegase i le lalolagi i se taimi vave."

OA MEA E AVEA MAI LENEI TUSI:

After successfully co-leading the phase II clinical trial of KX-826 in China for the treatment of AGA, Professor Zhang Jianzhong from Peking University People’s Hospital and Professor Yang Qinping from Huashan Hospital affiliated to Fudan University cooperate again to be the leading principal investigators (leading PIs) of the pivotal Phase III Clinical Trial of KX-826.
At the investigator meeting, nearly 100 experts from 26 hospitals across China listened to the report on the efficacy and safety of the KX-826’s Phase II clinical trial.
With the goal of completing the phase III clinical trial this year, we are speeding up the process and expecting that KX-826 would benefit global patients as soon as possible.